131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Background : Most older patients (pts) with relapsed or refractory (R/R) AML cannot tolerate intensive treatment and are not eligible for curative allogeneic hematopoietic cell transplant (alloHCT). 131I-apamistamab, an anti-CD45 radioimmunoconjugate, delivers high dose targeted radiation to hematop...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.2159-2159
Hauptverfasser:	Seropian, Stuart, Foran, James M., Gyurkocza, Boglarka, Nath, Rajneesh, Choe, Hannah, Litzow, Mark R., Koshy, Nebu, Stiff, Patrick J., Tomlinson, Ben K., Abhyankar, Sunil, Abedin, Sameem, Chen, George, Al-Kadhimi, Zaid, Kebriaei, Partow, Sabloff, Mitchell, Orozco, Johnnie J., Jamieson, Katarzyna Joanna, Magalhaes-Silverman, Margarida, Van Besien, Koen, Schuster, Michael W., Law, Arjun D., Mayer, Sebastian A., Lazarus, Hillard M., Spross, Jennifer, Li, Kate L, Haeuber, Elaina, Vusirikala, Madhuri, Nahar, Akash, Sandmaier, Brenda M., Pagel, John, Giralt, Sergio A., Desai, Avinash, Abboud, Camille N.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!